DE602006013114D1 - Mikronisiertes tanaproget und zusammensetzungen damit - Google Patents

Mikronisiertes tanaproget und zusammensetzungen damit

Info

Publication number
DE602006013114D1
DE602006013114D1 DE602006013114T DE602006013114T DE602006013114D1 DE 602006013114 D1 DE602006013114 D1 DE 602006013114D1 DE 602006013114 T DE602006013114 T DE 602006013114T DE 602006013114 T DE602006013114 T DE 602006013114T DE 602006013114 D1 DE602006013114 D1 DE 602006013114D1
Authority
DE
Germany
Prior art keywords
compositions
magnesium stearate
microcrystalline cellulose
croscarmellose sodium
micronized tanaproget
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006013114T
Other languages
English (en)
Inventor
Arwinder Nagi
Ramarao Chatlapalli
Shamim Hasan
Rolland W Carson
Mohamed Ghorab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of DE602006013114D1 publication Critical patent/DE602006013114D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
DE602006013114T 2005-04-28 2006-04-26 Mikronisiertes tanaproget und zusammensetzungen damit Active DE602006013114D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67555105P 2005-04-28 2005-04-28
PCT/US2006/016020 WO2006116596A2 (en) 2005-04-28 2006-04-26 Micronized tanaproget and compostions containing same

Publications (1)

Publication Number Publication Date
DE602006013114D1 true DE602006013114D1 (de) 2010-05-06

Family

ID=37027926

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006013114T Active DE602006013114D1 (de) 2005-04-28 2006-04-26 Mikronisiertes tanaproget und zusammensetzungen damit

Country Status (17)

Country Link
US (3) US20060246128A1 (de)
EP (1) EP1877059B8 (de)
JP (3) JP5149160B2 (de)
CN (1) CN101166533A (de)
AT (1) ATE461701T1 (de)
AU (1) AU2006239284C1 (de)
BR (1) BRPI0610431A2 (de)
CA (1) CA2603594C (de)
CY (1) CY1110017T1 (de)
DE (1) DE602006013114D1 (de)
DK (1) DK1877059T3 (de)
ES (1) ES2340518T3 (de)
MX (1) MX2007013467A (de)
PL (1) PL1877059T3 (de)
PT (1) PT1877059E (de)
SI (1) SI1877059T1 (de)
WO (1) WO2006116596A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4958338B2 (ja) * 1999-05-04 2012-06-20 ワイス・エルエルシー プロゲステロン受容体モジュレーターとしてのシクロチオカルバメート誘導体
ES2340518T3 (es) * 2005-04-28 2010-06-04 Wyeth Llc Tanaproget micronizado y composiciones que lo contienen.
CN101166532B (zh) 2005-04-28 2011-06-22 惠氏公司 微粒化的他那普戈特、组合物及其制备方法
AU2006287925B2 (en) 2005-04-28 2012-03-01 Wyeth Compositions containing micronized tanaproget
MX2007013469A (es) * 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
MX2007015571A (es) 2005-06-09 2008-03-06 Wyeth Corp Composiciones de tanaproget que contienen etinilestradiol.
CA2710293A1 (en) * 2007-12-20 2009-07-02 Teva Women's Health, Inc. Dosage regimens and pharmaceutical compositions and packages for emergency contraception
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
CN102438610A (zh) 2009-04-24 2012-05-02 伊休蒂卡有限公司 双氯芬酸的新剂型
US9326997B2 (en) 2012-09-24 2016-05-03 Ahlam E. Elakkad Composition and method for treation Oligoovulation, Oligomenorrhea and Amenorrhea
CA3135273A1 (en) * 2013-12-12 2015-06-18 Almirall, S.A. Pharmaceutical compositions comprising dimethyl fumarate
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
SG10202103458QA (en) * 2015-04-06 2021-05-28 Janssen Pharmaceutica Nv Compositions containing ibrutinib
WO2017003951A1 (en) * 2015-06-29 2017-01-05 Phloronol, Inc. Solid pharmaceutical compositions of brown algae
EP3641736A1 (de) 2017-06-23 2020-04-29 Almirall, S.A. Pharmazeutische zusammensetzungen mit dimethylfumarat
CN117180214A (zh) * 2023-10-26 2023-12-08 杭州和泽坤元药业有限公司 一种地屈孕酮片剂组合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
JP4958338B2 (ja) * 1999-05-04 2012-06-20 ワイス・エルエルシー プロゲステロン受容体モジュレーターとしてのシクロチオカルバメート誘導体
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6544553B1 (en) * 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US6962908B2 (en) 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
KR20050013627A (ko) 2002-06-25 2005-02-04 와이어쓰 Ｐｒ 조절제로서의 사이클로티오카바메이트 유도체 및피부 질환을 치료하기 위한 이의 용도
TW200404548A (en) 2002-06-25 2004-04-01 Wyeth Corp Pharmaceutical composition containing cyclothiocarbamate derivatives in treatment of hormone-related conditions
US8404272B2 (en) * 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
TW200604137A (en) 2004-04-27 2006-02-01 Wyeth Corp Coupling process for generating reactive boron-containing derivatives of n-substituted pyrrole-2-carbonitriles to produce biaryls
US7582755B2 (en) * 2004-04-27 2009-09-01 Wyeth Cyanopyrrole-containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same
CN1953967B (zh) 2004-04-27 2013-03-13 惠氏公司 孕酮受体调节剂的纯化
JP5288796B2 (ja) * 2004-07-07 2013-09-11 ワイス・エルエルシー 周期的プロゲスチンレジメン及びキット
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
PT1778710E (pt) * 2004-08-13 2012-04-12 Wyeth Llc Derivados de tanaproget, metabolitos e suas utilizações
BRPI0514528A (pt) * 2004-08-20 2008-06-10 Wyeth Corp estrutura de receptores de progesterona
ES2340518T3 (es) 2005-04-28 2010-06-04 Wyeth Llc Tanaproget micronizado y composiciones que lo contienen.
MX2007013469A (es) 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
CN101184738B (zh) 2005-04-28 2012-05-23 惠氏公司 纯化型的tanaproget
AU2006287925B2 (en) 2005-04-28 2012-03-01 Wyeth Compositions containing micronized tanaproget
CN101166532B (zh) * 2005-04-28 2011-06-22 惠氏公司 微粒化的他那普戈特、组合物及其制备方法
MX2007015571A (es) 2005-06-09 2008-03-06 Wyeth Corp Composiciones de tanaproget que contienen etinilestradiol.

Also Published As

Publication number Publication date
US8513240B2 (en) 2013-08-20
JP2014205684A (ja) 2014-10-30
CN101166533A (zh) 2008-04-23
US20110091539A1 (en) 2011-04-21
WO2006116596A3 (en) 2006-12-14
JP5149160B2 (ja) 2013-02-20
MX2007013467A (es) 2008-01-21
AU2006239284B2 (en) 2011-03-31
JP2008539262A (ja) 2008-11-13
DK1877059T3 (da) 2010-05-31
US20130337058A1 (en) 2013-12-19
EP1877059B1 (de) 2010-03-24
CY1110017T1 (el) 2015-01-14
EP1877059B8 (de) 2010-05-19
AU2006239284C1 (en) 2011-07-28
SI1877059T1 (sl) 2010-07-30
WO2006116596A2 (en) 2006-11-02
BRPI0610431A2 (pt) 2012-10-23
CA2603594C (en) 2013-11-05
PT1877059E (pt) 2010-05-04
ES2340518T3 (es) 2010-06-04
AU2006239284A1 (en) 2006-11-02
PL1877059T3 (pl) 2010-07-30
JP2012255000A (ja) 2012-12-27
CA2603594A1 (en) 2006-11-02
ATE461701T1 (de) 2010-04-15
EP1877059A2 (de) 2008-01-16
US20060246128A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
DE602006013114D1 (de) Mikronisiertes tanaproget und zusammensetzungen damit
TW200716129A (en) Micronized tanaproget, compositions, and methods of preparing the same
DK1874278T3 (da) Sammensætninger indeholdende mikroniseret tanaproget
TW200716621A (en) Polymorph form II of tanaproget
TW200731969A (en) Use of progesterone receptor modulators
Engel et al. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone
BR0006265A (pt) Composto de tetrahidroisoquinolinas como agonistas/antagonistas de estrogênios
IN2012DN05078A (de)
RU2016119135A (ru) Производные пиразолопиримидона или пирролотриазона, способ их получения и их фармацевтические применения
EA201491344A1 (ru) Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона
ATE515493T1 (de) Mercaptophenylnaphthylmethan-derivate und deren herstellung
AU2003255820A8 (en) Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer
DE602005019905D1 (de) -modulatoren
NZ515353A (en) Cyclothiocarbamate derivatives as progesterone receptor modulators
ATE512985T1 (de) Diagnostische und therapeutische anwendungen von löslichem lhcgr-protein
ATE275973T1 (de) Empfängnisverhütende zusammensetzungen die progestagen und progesteronantagonisten enthalten
ATE412631T1 (de) Indolderivate als progesteron-rezeptormodulatoren
MX2009009515A (es) Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona.
DK1345907T3 (da) 7-Heterocyclyl-quinolin- og thieno-2,3-B-pyridin-derivater anvendelige som antagonister af gonadotropin-frigörende hormon
TH58099B (th) การใช้ และสารผสมแอนติโปรเจสตินในการรักษาโรคต่อมลูกหมาก
AR023854A1 (es) Uso de derivados de indolina y equipo farmaceutico para regimenes ciclicos

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: WYETH LLC, WILMINGTON, DEL., US

8327 Change in the person/name/address of the patent owner

Owner name: WYETH LLC, MADISON, N.J., US

8328 Change in the person/name/address of the agent

Representative=s name: PATENT- UND RECHTSANWAELTE KRAUS & WEISERT, 80539

8364 No opposition during term of opposition